Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk
1. In the randomized COBRRA trial, apixaban was associated with substantially less clinically relevant bleeding than rivaroxaban in patients with ...
Tag: rivaroxaban
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]
Pfizer’s Talzenna combo significantly delays progression in frontline prostate cancer Topline results from the Phase 3 TALAPRO-3 study indicate that ...
![siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2015/04/clot-CCWiki-350x250.jpg)
Apixaban reduces bleeding risk versus rivaroxaban in acute venous thromboembolism
1. In a randomized controlled trial of patients with acute venous thromboembolism, apixaban was associated with a substantially lower risk ...
#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Abelacimab reduces bleeding risk compared to rivaroxaban in atrial fibrillation
1. In this randomized controlled trial, abelacimab led to significantly lower rates of major or clinically relevant nonmajor bleeding compared ...
Direct oral anticoagulants have similar bleeding risk compared with aspirin
1. In this systematic review and meta-analysis, the non-vitamin K oral anticoagulants apixaban and dabigatran both had similar rates of ...
#VisualAbstract: Abelacimab is Safer Than Rivaroxaban in Patients with Atrial Fibrillation
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Early oral anticoagulation is non-inferior to delayed treatment in patients with ischemic stroke and atrial fibrillation
1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or ...
Apixaban is associated with a lower risk of gastrointestinal bleeding than other direct oral anticoagulants
1. In this population-based cohort study, apixaban was associated with a lower risk of gastrointestinal bleeding (GIB) as compared to ...
Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease
1. In comparison to rivaroxaban, apixaban was associated with a lower rate of bleeding events and embolic events amongst adults ...
